Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000459384 | SCV000549055 | pathogenic | Gorlin syndrome | 2020-08-26 | criteria provided, single submitter | clinical testing | Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PTCH1 are known to be pathogenic (PMID: 16301862, 16419085). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Disruption of this splice site has been observed in individual(s) with nevoid basal cell carcinoma syndrome (PMID: 16301862, Invitae). ClinVar contains an entry for this variant (Variation ID: 409158). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 11 of the PTCH1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005049559 | SCV005679697 | pathogenic | Basal cell carcinoma, susceptibility to, 1; Holoprosencephaly 7; Basal cell nevus syndrome 1 | 2024-01-05 | criteria provided, single submitter | clinical testing |